Is Adaptive Biotechnologies Corp (ADPT) overvalued? · rev $179.0M
Adaptive Biotechnologies Corp (ADPT) is a diagnostics & research company listed on NASDAQ.
This page asks whether Adaptive Biotechnologies Corp (ADPT) looks expensive on cached numbers — not a short thesis.
Latest reported ADPT revenue for 2024-12-31 was $179.0M. Net income was -$159.6M. Revenue was up 5.1% from 2023-12-31 to 2024-12-31. ADPT currently screens at market cap $2.69B.
ADPT currently screens at market cap $2.69B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ADPT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ADPT stock page for the full model, not this heading.
Not investment advice.